Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Regeneron Pharmaceuticals, Inc. REGN
$746.67
+$1.1 (0.15%)
На 18:00, 12 мая 2023
+2.80%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
79716440500.00000000
-
week52high
837.55
-
week52low
538.01
-
Revenue
12172900000
-
P/E TTM
19
-
Beta
0.22664300
-
EPS
38.07000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Equal-Weight | 04 авг 2022 г. |
| BMO Capital | Outperform | Outperform | 04 авг 2022 г. |
| SVB Leerink | Market Perform | Outperform | 25 июл 2022 г. |
| Cowen & Co. | Market Perform | Market Perform | 20 июл 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 15 июл 2022 г. |
| Canaccord Genuity | Buy | Buy | 16 сент 2022 г. |
| Piper Sandler | Overweight | Overweight | 13 сент 2022 г. |
| Wells Fargo | Overweight | Overweight | 12 сент 2022 г. |
| Barclays | Overweight | Overweight | 09 сент 2022 г. |
| Goldman Sachs | Buy | Buy | 03 окт 2022 г. |
| Cowen & Co. | Market Perform | Market Perform | 20 окт 2022 г. |
| Evercore ISI Group | In-Line | Outperform | 17 окт 2022 г. |
| Raymond James | Underperform | Market Perform | 26 окт 2022 г. |
| EF Hutton | Buy | 01 ноя 2022 г. | |
| Guggenheim | Buy | Buy | 11 ноя 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 04 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 04 ноя 2022 г. |
| Morgan Stanley | Overweight | Overweight | 04 ноя 2022 г. |
| EF Hutton | Buy | Buy | 11 янв 2023 г. |
| Cowen & Co. | Outperform | Market Perform | 30 янв 2023 г. |
| Morgan Stanley | Overweight | Overweight | 24 янв 2023 г. |
| JP Morgan | Overweight | Neutral | 20 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| McCourt Marion | D | 7650 | 1100 | 01 февр 2023 г. |
| McCourt Marion | D | 22079 | 1100 | 01 февр 2023 г. |
| McCourt Marion | A | 23179 | 1100 | 01 февр 2023 г. |
| RYAN ARTHUR F | D | 19247 | 2 | 01 февр 2023 г. |
| RYAN ARTHUR F | D | 19249 | 3 | 01 февр 2023 г. |
| RYAN ARTHUR F | D | 19252 | 4 | 01 февр 2023 г. |
| RYAN ARTHUR F | D | 19256 | 4 | 01 февр 2023 г. |
| RYAN ARTHUR F | D | 19260 | 7 | 01 февр 2023 г. |
| RYAN ARTHUR F | D | 19267 | 2 | 01 февр 2023 г. |
| RYAN ARTHUR F | D | 19269 | 24 | 01 февр 2023 г. |
Новостная лента
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
MarketBeat
05 мая 2023 г. в 06:35
Regeneron Pharmaceuticals Inc. NASDAQ: REGN gapped down more than 6% on May 4, despite reporting better-than-expected first-quarter earnings and revenue.
Why Regeneron Pharmaceuticals Stock Is Tanking Today
The Motley Fool
04 мая 2023 г. в 13:23
Regeneron Pharmaceuticals posted overall positive 2023 Q1 results today. Even so, investors are concerned about the competitive positioning of the drugmaker's blockbuster eye-care treatment.
Regeneron (REGN) Q1 Earnings and Revenues Top Estimates
Zacks Investment Research
04 мая 2023 г. в 09:07
Regeneron (REGN) came out with quarterly earnings of $10.09 per share, beating the Zacks Consensus Estimate of $9.25 per share. This compares to earnings of $11.49 per share a year ago.
Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker
Investors Business Daily
04 мая 2023 г. в 08:50
Regeneron Pharmaceuticals beat first-quarter sales and profit calls, but Eylea revenue came up short and REGN stock tumbled. The post Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker appeared first on Investor's Business Daily.
Regeneron tops Q1 estimates but lowers margin guidance, sending stock lower
Market Watch
04 мая 2023 г. в 07:36
Regeneron Pharmaceuticals Inc. ‘s stock REGN, +0.59% slid 4% premarket Thursday, after the company topped estimates for first-quarter earnings but lowered margin guidance for 2023. The Tarrytown, N.Y.